Moldovan F, Pelletier J P, Mineau F, Dupuis M, Cloutier J M, Martel-Pelletier J
Centre hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Quebec, Canada.
Arthritis Rheum. 2000 Sep;43(9):2100-9. doi: 10.1002/1529-0131(200009)43:9<2100::AID-ANR22>3.0.CO;2-#.
Treatment of normal cartilage with transforming growth factor beta (TGFbeta) can increase the synthesis of collagenase 3 by chondrocytes and mimic the in situ distribution of this enzyme in osteoarthritic (OA) cartilage, which occurs predominantly in the deep zone. In this study, we examined the elements of the TGFbeta system that are potentially relevant to this effect.
TGFbeta1 and TGFbeta2 levels in cultured cartilage explants were determined by enzyme-linked immunosorbent assay (ELISA). OA cartilage explants were treated with small latent TGFbeta1 complex in the presence of various inhibitors, and collagenase 3 levels were determined by ELISA. The inhibitors were against serine proteases, plasmin, cathepsins, furin, and a neutralizing antibody against the mannose-6 phosphate/ insulin-like growth factor 2 receptor (M6P/IGF-2R). Small latent TGFbeta1, TGFbeta receptor types I, II, and III (TGFbetaRI, RII, and RIII), M6P/IGF-2R, and furin were immunolocalized in cartilage.
Our data showed that latent TGFbeta1 is the major isoform that is synthesized; levels of 17.2 +/-1.7 pg/mg and 1.1 +/- 0.3 pg/mg tissue wet weight (mean +/- SEM) were found for total TGFbeta1 and TGFbeta2, respectively, in OA cartilage. A general serine protease inhibitor abrogated activation of both endogenous and exogenous small latent TGFbeta1. Plasmin and furin inhibitors and anti-M6P/IGF-2R reduced the levels of exogenous small latent TGFbeta1 complex-induced collagenase 3 by 33%, 95%, and 76%, respectively, but the cathepsin inhibitor had no effect. Immunolocalization of the small latent TGFbeta1 complex as well as of TGFbetaRI and RII revealed a statistically significant increase in the chondrocyte score in only the deep zone of OA cartilage. The M6P/IGF-2R level was significantly higher in OA cartilage in both the superficial and deep zones. Furin was found in normal cartilage exclusively in the superficial zone, whereas in OA cartilage, a level similar to that in normal cartilage was found in the superficial zone, but a significantly higher cell score (mean +/- SEM 23.6 +/- 4.7%) was registered in the deep zone.
The mechanisms of TGFbeta activation/ activity with regard to collagenase 3 modulation in cartilage appear to be controlled by furin convertase with or without M6P/IGF-2R. These factors and the small latent TGFbeta complex are increased in the deep zone of OA cartilage, corresponding to the preferential site of collagenase 3 production.
用转化生长因子β(TGFβ)处理正常软骨可增加软骨细胞中胶原酶3的合成,并模拟该酶在骨关节炎(OA)软骨中的原位分布,这种分布主要发生在深层区域。在本研究中,我们检测了TGFβ系统中可能与这种作用相关的成分。
通过酶联免疫吸附测定(ELISA)法测定培养的软骨外植体中TGFβ1和TGFβ2的水平。在各种抑制剂存在的情况下,用小潜伏TGFβ1复合物处理OA软骨外植体,并通过ELISA法测定胶原酶3的水平。这些抑制剂针对丝氨酸蛋白酶、纤溶酶、组织蛋白酶、弗林蛋白酶,以及一种针对甘露糖-6-磷酸/胰岛素样生长因子2受体(M6P/IGF-2R)的中和抗体。对小潜伏TGFβ1、I型、II型和III型TGFβ受体(TGFβRI、RII和RIII)、M6P/IGF-2R和弗林蛋白酶进行软骨中的免疫定位。
我们的数据表明,潜伏TGFβ1是合成的主要异构体;OA软骨中总TGFβ1和TGFβ2的水平分别为17.2±1.7 pg/mg和1.1±0.3 pg/mg组织湿重(平均值±标准误)。一种通用的丝氨酸蛋白酶抑制剂可消除内源性和外源性小潜伏TGFβ1的激活。纤溶酶和弗林蛋白酶抑制剂以及抗M6P/IGF-2R分别使外源性小潜伏TGFβ1复合物诱导的胶原酶3水平降低33%、95%和76%,但组织蛋白酶抑制剂无作用。小潜伏TGFβ1复合物以及TGFβRI和RII的免疫定位显示,仅在OA软骨的深层区域软骨细胞评分有统计学显著增加。OA软骨的浅层和深层区域M6P/IGF-2R水平均显著升高。弗林蛋白酶仅在正常软骨的浅层区域发现,而在OA软骨中,浅层区域的水平与正常软骨相似,但深层区域的细胞评分显著更高(平均值±标准误23.6±4.7%)。
TGFβ在软骨中对胶原酶3调节的激活/活性机制似乎由弗林蛋白酶转化酶控制,可能有或没有M6P/IGF-2R参与。这些因子和小潜伏TGFβ复合物在OA软骨的深层区域增加,与胶原酶3产生的优先部位相对应。